Cynapsus Therapeutics Is First to Develop Convenient Delivery of Apomorphine for Parkinson's Patients Experiencing "OFF" Episodes, Says Zacks Analyst via Interview With the Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Aug 5, 2013) - Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Cynapsus Therapeutics Inc. (OTCQX: CYNAF) (TSX VENTURE: CTH) is a small Canadian company developing a sublingual formulation of a drug called apomorphine, which is a rescue medication for Parkinson's disease patients who experience something called 'off time,' a rigid or frozen state that occurs when their levodopa + carbidopa medication has worn off. This typically happens in the morning, because the Parkinson's patient takes his or her last dose of medication before bed, and it has worn off by the time they awaken. Apomorphine is a rapid rescue medication for that "off time" state. Cynapsus' sublingual film formulation of apomorphine is put under the tongue and dissolves in a very short period of time. Patients with dyskinesia can take it themselves. It just makes sense.

"I think it could be a $500M or more opportunity. Parkinson's is an enormous indication, and almost all Parkinson's patients experience this on/off phenomenon. This is a very clean, low-risk story, and I love the way Cynapsus has pulled this off, being the first to patent this delivery. If this were a U.S. stock, it would be four or five times the price it is now, but because it's in Canada, no one knows about it."

Continue reading this interview with Jason Napodano, "Off to the Races with Seven Extraordinary Biotech and Medtech Companies."

To Read Jason Napodano's comments on other companies, visit The Life Sciences Report.

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide valuable insights, integrated with in-depth company information, summaries from the latest research, and news that will help you make smart investment decisions.